March 22nd 2023
Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.
March 15th 2023
An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.
Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.
March 8th 2023
Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.
A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.
March 1st 2023
A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.
Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.
February 22nd 2023
Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.
Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.
February 15th 2023
Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.
Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.
November 9th 2022
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
November 2nd 2022
In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
October 26th 2022
Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
October 19th 2022
Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.